- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior
A panel of experts discusses the ways in which payers restrict prescribing choices for physicians and what that means for the future of biosimilar utilization.
On July 20, 2020, MJH Life Sciences™ hosted the webinar "How Biosimilar Rebates Shape Payer Policies, Provider Behavior." Jeff Prescott, PharmD, senior vice president of Clinical Communications for MJH Life Sciences™ served as moderator. The panelists were Kathy Oubre, MS, chief operating officer of the Pontchartrain Cancer Center in Louisiana; Timothy Chiu, PharmD, BCPS, pharmacist evidence analyst and strategist for Kaiser Permanente; and Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator of Hematology/Oncology for The University of Arizona Cancer Center in Tucson.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
